| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T85616 | ||||
| Target Name | Thioredoxin | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | PX-12 | Drug Info | Ki = 0.5 nM | [552866] | |
| Action against Disease Model | PX-12 | The disulfides inhibited the thioredoxin dependent proliferation of MCF-7 breast cancer cells with ICso values of 1.2 pM, respectively Based on previous studies PX-12 has IC50 value of about 1.2FM. | Drug Info | ||
| The Effect of Target Knockout, Knockdown or Genetic Variations | Mesangial cell apoptosis contributes to the pathogenesis of diabetic nephropathy. Here we show that thioredoxin interacting protein (TXNIP) is involved in high glucose (HG)-induced mouse mesangial cell (MMC) apoptosis. HG induced activation of apoptosis signal regulating kinase-1 (ASK1) in a time-dependent manner in MMCs. Treatment with antioxidant, tempol, or knockdown of TXNIP in MMCs reduced HG-mediated apoptosis, expression of cleaved caspase-3, Bax/Bcl-2 ratio and activation of ASK1. These data suggest that knockdown of TXNIP prevented HG-induced cell apoptosis and activation of ASK1 may be via reduction of oxidative stress in MMCs | [552866] | |||
| References | |||||
| Ref 552866 | Dopamine D5 receptors: a challenge to medicinal chemists. Mini Rev Med Chem. 2008 Sep;8(10):976-95. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.